BOT - Anything but charting, page-8366

Just some thoughts from a overthinking relatively new BOT investor. . .

After digesting the webinar and reading between the lines I am now convinced the IT platforms that will underpin the sofdra release will be company making in their own right. . .

It is quite possible that the "instructions for use" were actually available but were intended to be included digitally within the SOFRA app/platform to draw patients/practitioners into the IT ecosystem. BUT . . . the FDA needed the paper written ones included.

This would explain why the resubmission was so timely.

I have said it before but I think BOT is waiting for FDA approval not only for drug commercialisation but also for showcasing the revolutionary IT platforms. . . script refill, practitioner/patient care (aka aftercare)

Then other companies can pay us $$$ for product release and the aftercare . . .

AIMO